Streetbeat News

Stock Prices

REGN

Trading of Regeneron Pharmaceuticals shares has resumed following a news halt.

Portfolio Pulse from Happy Mohamed

June 27, 2023 | 7:15 pm

NKTX

Nkarta Inc's Phase 1 study of NKX101 for treating acute myeloid leukemia (AML) has been deemed a setback by Needham, leading to a revised development timeline and a lowered price target from $26 to $19. The company plans to enroll more patients in the trial and provide an update in 1H 2024. NKTX shares are down 35.50% at $2.92.

Portfolio Pulse from Vandana Singh

June 27, 2023 | 7:13 pm

CCL

RCL

Carnival Corp (CCL) reported upbeat Q2 FY23 results, with 2023 EBITDA raised to $4.1-4.25 billion and long-term targets ahead of expectations. CCL also announced its SEA Change Program, setting performance targets through 2026. Analysts from BofA Securities, Truist Securities, and Susquehanna provided their views on the results and set new price targets. CCL shares traded higher by 8.2% at $15.80.

Portfolio Pulse from Shivani Kumaresan

June 27, 2023 | 7:11 pm

ACET

JMP Securities has downgraded Adicet Bio Inc (NASDAQ:ACET) to a Market Perform and removed the price target of $19 due to uncertainty regarding the start of pivotal studies. The rating is based on an expected cash balance of $114.3 million at the end of Q1 2024, with 43.1 million shares outstanding, resulting in a value of $2.65. The shares have tanked after the company released shared safety and efficacy data from its Phase 1 study of ADI-001 for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma (NHL).

Portfolio Pulse from Vandana Singh

June 27, 2023 | 7:08 pm

GFI

Gold Fields shares are trading lower due to a drop in gold prices following strong US economic data.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 7:07 pm

ACET

BDTX

CNTG

RIDE

SNX

SYTA

TIVC

U.S. stocks traded higher with the Nasdaq Composite gaining over 200 points. TD Synnex Corp reported worse-than-expected Q2 results and issued Q3 guidance below estimates. Centogene N.V., Black Diamond Therapeutics, and Tivic Health Systems saw their shares rise due to various positive developments. Lordstown Motors Corp filed for Chapter 11 bankruptcy, Adicet Bio shared disappointing data from its Phase 1 study, and Siyata Mobile priced a 50 million share offering, leading to a drop in their shares.

Portfolio Pulse from Lisa Levin

June 27, 2023 | 7:04 pm

FCX

A significant amount of unusual options activity has been observed for Freeport-McMoRan (NYSE:FCX), with a majority of investors taking a bullish stance. The targeted price range for the company over the last three months has been between $25.0 and $45.0. The current price of FCX is up 2.92% at $40.41, and the next earnings are expected in 23 days. Morgan Stanley has maintained their Equal-Weight rating on Freeport-McMoRan with a price target of $38.

Portfolio Pulse from Benzinga Insights

June 27, 2023 | 7:03 pm

CVX

A whale investor has taken a bearish stance on Chevron (NYSE:CVX), with 70% of the spotted trades being bearish. The whales have been targeting a price range from $140.0 to $210.0 for Chevron over the last 3 months. The price of CVX is currently down -0.31% at $153.54. JP Morgan, RBC Capital, and Piper Sandler have upgraded their ratings on Chevron with price targets of $170, $180, and $188 respectively.

Portfolio Pulse from Benzinga Insights

June 27, 2023 | 7:03 pm

GMS

Truist Securities analyst Keith Hughes has reiterated a Hold rating on GMS Inc. (NYSE:GMS) and raised the price target to $72 from $60. GMS reported Q4 FY23 sales growth of 1.2% Y/Y to $1.304 billion, surpassing the consensus of $1.27 billion. The analyst increased the FY 2024 EBITDA estimate to $596 million from $507 million. However, Hughes believes that the housing outlook and potential pressure on wallboard pricing will limit multiple expansions.

Portfolio Pulse from Nabaparna Bhattacharya

June 27, 2023 | 7:02 pm

AHCO

AdaptHealth (NASDAQ:AHCO) has received mixed analyst ratings in the last quarter, with 3 bullish, 3 somewhat bullish, and 3 indifferent ratings. The average 12-month price target for the company has decreased by 26.77% from $21.44 to $15.7. Analysts determine these ratings based on the company's future earnings potential and the predictability of its revenue streams.

Portfolio Pulse from Benzinga Insights

June 27, 2023 | 7:01 pm